Hoth Therapeutics, Inc. (HOTH): Price and Financial Metrics
GET POWR RATINGS... FREE!
HOTH Stock Price Chart Interactive Chart >
HOTH Price/Volume Stats
|Current price||$1.59||52-week high||$3.89|
|Prev. close||$1.60||52-week low||$1.27|
|Day high||$1.60||Avg. volume||3,407,167|
|50-day MA||$1.56||Dividend yield||N/A|
|200-day MA||$1.92||Market Cap||37.96M|
Hoth Therapeutics, Inc. (HOTH) Company Bio
Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.
HOTH Latest News Stream
|Loading, please wait...|
HOTH Latest Social Stream
View Full HOTH Social Stream
Latest HOTH News From Around the Web
Below are the latest news stories about Hoth Therapeutics Inc that investors may wish to consider to help them evaluate HOTH as an investment opportunity.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement with Washington University in St. Louis to support the continued research and development of HT-ALZ, a novel therapeutic for the treatment of symptoms related to Alzheimer's disease.
Hoth Therapeutics Inc (NASDAQ: HOTH) has reported results from a preclinical trial of HT-KIT, a new molecular entity under development to treat mast cell-derived cancers and anaphylaxis. HT-KIT is an mRNA frame-shifting therapeutic designed to specifically target the receptor tyrosine kinase KIT, which is required for the proliferation, survival, and differentiation of bone marrow-derived hematopoietic stem cells. Key findings of the mouse models found that HT-KIT: Reduces KIT expression and ind
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will share positive results from a preclinical trial during its shareholder presentation, reinforcing the potential of HT-KIT, a new molecular entity under development for treatment of mast cell-derived cancers and anaphylaxis.
Hoth Therapeutics Plans Shareholder Presentation on HT-KIT Therapeutic's Preclinical Results for Rare Cancers
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today plans to host a virtual information session on its pipeline product, HT-KIT, a new molecular entity under development for treatment of mast cell-derived cancers and anaphylaxis, on Thursday, June 3rd for interested shareholders. Dr. Glenn Cruse, Ph.D., Assistant Professor at North Carolina State University, who developed HT-KIT, will present the preclinical animal results that are part of the Company's ASCO Exhibition.
HOTH Price Returns